Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 long-term extension study of abrocitinib in moderate to severe atopic dermatitis
NL-OMON54631Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of abrocitinib, sponsored by Pfizer. Started Jul 2019; status: active, not recruiting.
02
Drugs
abrocitinib
Beyond the preview
Go deeper on NL-OMON54631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54631.